Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The University of Texas M D Anderson Cancer Center and AstraZeneca have announced that they will collaborate to help advance understanding of neuropathic pain caused by cancer chemotherapy, a side effect that often limits optimal therapeutic dosing in cancer treatments.
Subscribe to our email newsletter
The new alliance will focus on identifying neurobiological differences between cancer patients who develop chemotherapy-induced pain and patients who experience little or no pain. Scientists at M D Anderson and AstraZeneca hope to better understand the mechanisms through which chemotherapies cause peripheral nerve dysfunctions, such as numbness and tingling, and severe pain. Research could lead to new treatments to prevent pain, extending the therapeutic value of current chemotherapies, as well as help in the development of new chemotherapies with less severe pain-related side effects.
M D Anderson and AstraZeneca have ongoing collaborations focused on a variety of initiatives across a range of AstraZeneca oncology products and research projects. This new agreement will extend that relationship to examine one of the most prevalent symptoms in cancer patients. One study found that pain affects up to 50% of patients undergoing active cancer treatment and up to 90% of those with advanced disease.